SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Concerns over CoreWeaves debt-funded data-center expansion and access to financing dominate the discussion, amplified by HSBCs bearish assessment of debt costs and AI-demand risks. Bears warn of further downside and question insider selling, while bulls point to contracted demand, Goldmans more positive view and ARKs buying as reasons the selloff may be overdone.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb amid reported attacks on Middle East shipping and energy infrastructure, raising fears of supply disruptions around the Strait of Hormuz. Traders are split between betting that geopolitical risks will keep oil elevated and expecting prices to retreat if shipping conditions improve or diplomacy eases tensions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a slide to record lows, which traders associate with fading confidence in Trump ahead of the midterms and concerns about the companys limited operating business. The conversation is overwhelmingly bearish, though some traders point to a possible trading bounce or the pending TAE fusion deal as potential offsets.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

Barclays downgrade to Underweight has intensified selling, with traders focused on commercial execution risk and the lack of a definitive TVAENTRA1 agreement for NuScales proposed deployment. Bears see delayed contracts as evidence the business case is faltering, while some bulls view the selloff as overdone and are waiting for concrete project progress.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces agreement to acquire customer-engagement platform Braze is driving discussion, with the deal framed as an expansion of its AI-powered marketing capabilities. Traders are reacting to CRMs weakness and debating the acquisitions cost and strategic value, while watching technical support levels.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is falling despite a quarterly earnings beat and a new multiyear share-repurchase authorization, as traders focus on a full-year profit outlook whose midpoint was unchanged rather than raised. The community is split between buyers who see strong cash generation and the buyback as support, and skeptics who argue the outlook and sales pressures outweigh those positives.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

CEO Angelos Stergious 15th-anniversary LinkedIn post about the companys next chapter with GPS and SLS009 has fueled speculation about a potential buyout and imminent clinical news, though neither was confirmed. Discussion also centers on the REGAL Phase 3 trials final analysis, triggered at 80 deaths versus 78 last disclosed: bulls view the extended wait as potentially encouraging, while skeptics say the blinded trials timing cannot establish efficacy and question managements communication.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USAR is drawing attention after a prolonged selloff toward 52-week lows, alongside weakness across rare-earth and critical-minerals stocks. Traders debate whether the decline reflects sector pressure and concerns about potential dilution, cash burn, and the time needed to reach production; some blame short sellers or management, while others view the shares as oversold and point to the companys strategic U.S. supply-chain role.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTXs quarterly results topped expectations and management raised its full-year outlook, with traders pointing to strong aerospace and defense demand and a record backlog. The upbeat results have drawn bullish reactions, though some traders are frustrated that the share price has not responded more strongly.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under heavy selling pressure amid repeated lockup expirations and reported insider sales, with traders also citing a lower analyst price target and concerns about OpenAI customer concentration and competition. Bearish calls for further declines contrast with bulls arguing the selloff is overdone and the companys AI-chip technology has long-term potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround 

Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial

Equity

Prelude expects patient enrollment to begin in Q4 2026, starting with monotherapy dose escalation before advancing to combination cohorts.


Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million.
Prelude Therapeutics (NASDAQ:PRLD) shares movedread more...

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Recommendation of "Hold" by Analysts

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) has earned an average rating of 'Hold' from the five brokerages that are presently covering the stock, Marketbeat.com reports. One...

Prelude Therapeutics (NASDAQ:PRLD) Coverage Initiated by Analysts at D. Boral Capital

D. Boral Capital initiated coverage on shares of Prelude Therapeutics in a research note on Monday. They set a 'buy' rating and a $9.00 price target on the stock...

Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research

Zacks Research raised Prelude Therapeutics to a "hold" rating in a research report on Tuesday...

Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday

Prelude Therapeutics (NASDAQ:PRLD) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-prelude-therapeutics-incorporated-stock...

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Prelude Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Under the agreement, Lilly will supply abemaciclib, marketed as Verzenio, and Imlunestrant, marketed as Inluriyo.</li><li>The Phase 1 trial will evaluate combinations of PRT13722, an oral KAT6A selective degrader, with these medicines in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer.</li><li>The FDA cleared Prelude to proceed with the study under its Investigational New Drug (IND) application.</li></ul>Prelude Therapeutics (PRLD) announced a clinical trial collaboration and supply agreement with Eli Lilly and Company (LLY) on Tuesday to evaluate its experimental breast cancer drug PRT13722 in combination with two Lilly medicines.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/PRLD">PRLD shares</a> were down more than 7%, while&nbsp;<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> traded 1.5% lower. The iShares Biotechnology ETF (<a href="https://stocktwits.com/symbol/IBB">IBB</a>) declined over 1.5%.<h2 class="st-heading-2">What Does The Lilly Collaboration Involve?</h2>Under the agreement, Lilly will supply Abemaciclib, marketed as Verzenio, and Imlunestrant, marketed as Inluriyo. The Phase 1 trial will evaluate combinations of PRT13722, an oral KAT6A selective degrader, with these medicines in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer.The FDA cleared Prelude to proceed with the study under its Investigational New Drug (IND) application. The company expects enrollment to begin in the fourth quarter of 2026, starting with monotherapy dose escalation before advancing to combination cohorts.Sean Brusky, Prelude’s chief business and strategy officer, said: “Our preclinical data demonstrate that selectively degrading KAT6A has the potential to improve upon the efficacy and hematologic toxicity seen with dual KAT6A/B inhibitors.” He added that the approach could enable combination treatments that may advance the standard of care in earlier lines of therapy.<h2 class="st-heading-2">What Has Prelude Reported About PRT13722?</h2>At the&nbsp;American Association for Cancer Research (AACR) 2026 Annual Meeting in April, Prelude presented preclinical data showing that PRT13722 produced durable complete tumor regressions as a monotherapy in HR+/HER2- breast cancer cell-line-derived and patient-derived xenograft models at well-tolerated doses.The company also reported synergy when PRT13722 was combined with endocrine therapies, CDK4/6 inhibitors and PI3K inhibitors across HR+ breast cancer models, including ESR1-mutated and acquired therapy-resistant cancer cells.Prelude said the candidate demonstrated an improved hematological safety profile compared with prifetrastat, a dual KAT6A/B inhibitor, in preclinical testing.&nbsp;<h2 class="st-heading-2">How Retail Views PRLD, LLY</h2>Retail sentiment for both PRLD and LLY on Stocktwits remained in ‘Bearish’ territory over the past 24 hours.One Stocktwits user praised PRLD’s collaborations.<stembedurl>https://stocktwits.com/Bernardbaruch1/message/666375649</stembedurl>PRLD shares have risen more than 48% year to date, while LLY shares have gained more than 8% over the same period.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/robinhood-gets-a-price-target-hike-from-truist-as-wall-street-s-earnings-outlook-improves/cZxBnkORBYg">Robinhood Gets A Price Target Hike From Truist As Wall Street’s Earnings Outlook Improves</a>For updates and corrections, email newsroom@stocktwits.com

Young female scientist working in laboratory (Representative image courtesy of Solskin via Getty Images)

Prelude Therapeutics (PRLD) announced a clinical trial collaboration and supply agreement with Eli Lilly and Company (LLY) on Tuesday to evaluate its experimental breast cancer drug PRT13722 in combination with two Lilly medicines.

iShares Biotechnology ETF

Lilly(Eli) & Co

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$3.49
Prev Close	$3.39
Open	$3.38
Dividend Yield	0.00%
50-Day Moving Average	$4.78
Beta	1.89
Avg. Volume	500,491.14
PE Ratio	-4.30

52-Week High	$6.83
52-Week Low	$1.17
Market Capitalization	$270.53M
EPS (Annual)	-$1.29
Price to Book	2.02
Revenue Per Employee	$153,670.89

Feed

News

Sentiment

Earnings

Fundamentals

Info

PRLD Fundamentals